New Delhi: While Psilocybin – a Natural Compound Found in Certain Mushrooms – Has Shown Promise in Treating Depression and Anxiety, Anxiety, A New Study Showed Itfits in Lifting Mood and Enehansting Motor Symptoms in Parkinson's Disease Patients.

Researchers from the University of California San Francisco Showed that psilocybin can be used Symptoms and do't respond well to antidepressants or other medicines.

The team conducted a pilot on Seven men and five women with mild to moderate parkinson's disease. They were prescribed a psilocybin of 10 mg dose, followed two weeks laater by a higher dose of 25 mg.

The findings, published in the journey neuropsychopharmacology, showed that the drug was tolerated without any serial side effects or Worsening Symptoms.

The pilot study also showed clinically significant improvements in mood, cognition, and motor function that laasted for weeks after the Drug was out of the Participant's Systems.

It is the first time a psychedelic has been tested on patients with any neurodegenerastic disease.

“We are still in very early stages of this work, but this first study went well beyond what we expected,” said ellen Bradley, Assistant Professor and Associate Director of Ucsf ' Psychedelic Research Program (TRPR).

“Many people do't realise this, but mood symptoms in parkinson's are linked to a faster physical decline,” She said. “And they are actually a stronger predictor of patients' Quality of life with parkinson's than their motor symptoms.”

Parkinson's disease is a progressive neurodegenerative disorder, characterized by unconstrolled movements due to abnormal brain activity.

While medicines like Levodopa can relieve symptoms, there are no approved therapies to slow the program or revrees the disease its item.

Common Early physical symptoms include tremors and foot-dragging, but bradley said anxiety and depression in patients with no history of psychiatric problems ofne preceded Symptoms by Several Years.

It's Unclear Why Standard Medias often Do's Work Well for these patients, but mood changes should be part of the neurodegenerable disease process, the team said.